• In late May 2026, Elevance Health Inc. highlighted its Get Connected for Health program and CareBridge services, which provide free smartphones, tablets, connectivity, and multilingual virtual care to help underserved members overcome the digital divide and better manage their healthcare.
• By embedding digital access directly into care delivery for Medicaid, Dual-Special Needs, and long-term support populations, Elevance Health is tying its growth in value-based services to a broader push for digital equity and more consistent, data-rich member engagement.
• We’ll now examine how Elevance Health’s push into digitally enabled, value-based care through programs like Get Connected for Health affects its investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Elevance Health Investment Narrative Recap

To own Elevance Health, you need to be comfortable with a heavily regulated, government-focused insurer that is trying to offset medical cost pressure through tech-enabled, value-based care. Programs like Get Connected for Health and CareBridge support that story by deepening digital engagement and data flows, but they do not change the near term balance between the key catalyst of services growth and the biggest risk of persistently elevated medical costs in Medicaid and ACA plans.

Among recent developments, the ongoing CMS review of Elevance’s Medicare Advantage data and potential sanctions stands out alongside this digital push. While Get Connected for Health and CareBridge highlight Elevance’s commitment to underserved populations, the CMS process sits much closer to the immediate risk and catalyst mix, because it directly affects government margins, rate negotiations, and how quickly Elevance can translate its Carelon and value-based care investments into steadier earnings.

But even with promising digital programs, investors should still pay close attention to how CMS decisions could reshape Elevance’s government margins and...

Elevance Health's narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and about a $2.0 billion earnings increase from $5.4 billion today.

Uncover how Elevance Health's forecasts yield a $387.85 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were expecting revenue of about US$214.7 billion and earnings of roughly US$7.3 billion by 2029, see Elevance’s value-based, digitally enabled care as a powerful margin and growth catalyst, while others focus more on how regulatory pressures and high medical costs could blunt those benefits, so it is worth comparing these very different views before you decide how this new connectivity push might shift the story.

Explore 10 other fair value estimates on Elevance Health - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

No Opportunity In Elevance Health?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.